CD274 and non-small cell lung carcinoma: After the good results of the initial study of ICIs in patients with metastatic NSCLC [5], several prospective randomized clinical trials have shown improved survival and tolerability with PD-1 and PD-L1 blockade in selected patients with advanced NSCLC [19,20].